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ABSTRACT
Objective The FORWARD (FGF-18 Osteoarthritis 
Randomized Trial with Administration of Repeated Doses) 
trial assessed efficacy and safety of the potential disease- 
modifying osteoarthritis drug (DMOAD) sprifermin in 
patients with knee osteoarthritis. Here, we report 5- year 
efficacy and safety results.
Methods Patients were randomised to intra- articular 
sprifermin 100 µg or 30 µg every 6 months (q6mo) or 12 
months, or placebo, for 18 months. The primary analysis 
was at year 2, with follow- up at years 3, 4 and 5. 
Additional post hoc exploratory analyses were conducted 
in patients with baseline minimum radiographic joint 
space width 1.5–3.5 mm and Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) 
pain 40–90, a subgroup at risk (SAR) of progression.
Results 378 (69%) patients completed the 5- 
year follow- up. A significant dose- response in total 
femorotibial joint cartilage thickness with sprifermin 
(trend test, p<0.001) and a 0.05 mm mean difference 
with sprifermin 100 µg q6mo versus placebo (95% CI 
0.00 to 0.10; p=0.015) were sustained to year 5. 
WOMAC pain scores improved ~50% from baseline in 
all groups. No patient in the 100 µg q6mo group had 
replacement of the treated knee. 96%–98% of patients 
receiving sprifermin and 98% placebo reported adverse 
events, most were mild or moderate and deemed 
unrelated to treatment. Adverse event- related study 
withdrawals were <10%. Differentiation in WOMAC pain 
between sprifermin 100 µg q6mo and placebo in the SAR 
(n=161) at year 3 was maintained to year 5 (−10.08; 
95% CI −25.68 to 5.53).
Conclusion In the longest DMOAD trial reported 
to date, sprifermin maintained long- term structural 
modification of articular cartilage over 3.5 years post- 
treatment. Potential translation to clinical benefit was 
observed in the SAR.
Trial registration number NCT01919164
INTRODUCTION
Current therapies for osteoarthritis (OA) focus 
on reducing pain, improving physical function 
and patient’s quality of life.1 2 There is an urgent 
need for disease- modifying osteoarthritis drugs 
(DMOADs) that improve symptoms and inhibit 
structural disease progression.3 4 Many DMOAD 
trials have had limited success or yielded negative 
results, with the heterogeneous nature of OA and 
insufficient trial follow- up times being potential 
contributors.5 6
Key messages
What is already known about this subject?
 ► Sprifermin is a potential disease- modifying 
osteoarthritis drug that was shown to increase 
articular cartilage thickness compared with 
placebo in patients with knee osteoarthritis at 
the primary endpoint (year 2) of the FORWARD 
trial and was well tolerated. Structural 
benefits with sprifermin were observed in a 
subgroup at risk (SAR) of progression, who 
also demonstrated improvements in pain over 
placebo at year 3 follow- up.
What does this study add?
 ► Here we show that long- term structural 
modification of articular cartilage was 
maintained with sprifermin versus placebo over 
a 3.5- year to 4- year post- treatment period. 
Similar maintenance of structural improvements 
over this time was seen in the SAR, and 
clinically relevant improvement in pain over 
placebo in this subgroup was also sustained up 
to year 5 follow- up.
 ► There were no target knee replacements in the 
highest dose group of sprifermin over 5 years 
and no new safety signals.
How might this impact on clinical practice or 
future developments?
 ► These findings confirm the long- term structural 
benefit of intra- articular sprifermin treatment, 
with potential long- term clinical benefit and 
disease modification for knee osteoarthritis and 
no safety concerns.
 ► Long- term follow- up in disease- modifying 
osteoarthritis drug trials may be required 
to ensure that translation of structural 
modification to clinical benefit is seen.
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Preservation of cartilage integrity is widely considered a highly 
important goal for a DMOAD.7 Sprifermin is a recombinant 
human fibroblast growth factor 18 that has cartilage regenerative 
properties and is under investigation as a potential DMOAD for 
knee OA.8–11 No measurable systemic effects or safety concerns 
were associated with sprifermin in phase I and Ib studies.12 13
FORWARD (FGF-18 Osteoarthritis Randomized Trial with 
Administration of Repeated Doses) was a 5- year, randomised 
clinical trial that evaluated the efficacy and safety of sprifermin 
among 549 patients with symptomatic radiographic knee OA.14 
FORWARD was designed with total femorotibial joint (TFTJ) 
cartilage thickness change as the primary structural endpoint at 
year 2, and change in Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) scores over the same 
period was a secondary endpoint. Follow- up continued up to 
year 5. The 2- year and 3- year data were reported recently: dose- 
dependent modification of TFTJ cartilage thickness with spri-
fermin was demonstrated at years 2 and 3, and a mean difference 
of 0.05 mm in TFTJ cartilage thickness between the highest spri-
fermin dose (100 µg every 6 months (q6mo); 0.03 mm gain) and 
placebo (0.02 mm loss) was observed.14 WOMAC total scores 
improved by around 50% in all cohorts but did not differ signifi-
cantly between sprifermin and placebo.14
Previous studies have revealed that including patients with 
at least moderate pain at baseline enables greater differenti-
ation of a pain response to treatment.7 In addition, inclusion 
of patients with advanced disease (eg, low radiographic joint 
space width (JSW)) may enhance the ability to observe disease 
progression15 and detect translation of structural modification 
to clinical benefit.16 Exploratory post hoc analyses were there-
fore conducted in a so- called ‘subgroup at risk’ (SAR) of patients 
in FORWARD, with narrower medial or lateral minimum JSW 
(mJSW) and higher WOMAC pain than the overall study popu-
lation at baseline (n=161).16 SAR placebo- treated patients had 
more rapid structural progression compared with the overall 
study population, whereas net TFTJ cartilage modification with 
sprifermin versus placebo was similar.16 Importantly, in the SAR, 
differentiation in WOMAC pain score change between placebo 
and the highest sprifermin dose was observed at year 3.16
Here, we report the long- term structural and symptomatic 
efficacy and safety of sprifermin in the overall FORWARD study 
population and SAR up to year 5, that is 3.5 (for the q6mo 
groups) or 4 years (for the q12mo groups) after the last spri-
fermin treatment.
PATIENTS AND METHODS
Study design and outcomes
FORWARD was a randomised, double- blind, dose- finding, 
placebo- controlled trial. The study design was reported 
previously.14 Patients at 10 centres in seven countries were 
randomised 1:1:1:1:1 to receive intra- articular sprifermin 100 
or 30 µg q6mo, 100 or 30 µg q12mo or placebo. Sprifermin was 
administered in cycles consisting of three injections over three 
consecutive weeks, q6mo (0, 6, 12, 18 months) or q12mo (0 and 
12 months, with placebo at months 6 and 18) over an 18- month 
period (online supplemental figure S1).
FORWARD consisted of a primary 2- year analysis period, with 
an extended 3- year observation period. The primary endpoint 
was change in TFTJ cartilage thickness in the target knee at year 
2, based on quantitative MRI (qMRI, see online supplemental 
materials). Secondary endpoints included change from base-
line in WOMAC scores (0–100, where 0 represents no symp-
toms), mJSW in the medial and lateral compartments assessed 
by fixed- flexion radiography, cartilage thickness in medial and 
lateral femorotibial compartments (MFTC and LFTC) by qMRI, 
and the incidence and nature of adverse events (AEs) over 2 
years. WOMAC assessments, which referenced the last 48 hours, 
were performed after a pain medication washout of at least 5 
half- lives.
Exploratory follow- up for all efficacy and safety endpoints 
was performed at years 3, 4 and 5. A change in WOMAC pain by 
≥10 (of 100) was described as a clinically relevant pain improve-
ment to be perceived by an individual.17 The incidence of knee 
replacements (KRs) in the treated knee was a key exploratory 
endpoint, added post hoc to the year 5 analyses.
The SAR included all patients with baseline medial or lateral 
mJSW of 1.5–3.5 mm and a WOMAC pain score of 40–90. Post 
hoc exploratory analyses were conducted in the SAR, including 
structural (qMRI- based cartilage thickness and radiographic 
mJSW), symptomatic (WOMAC scores) and safety endpoints up 
to year 5.
See online supplemental materials for details on statistical 
analyses.
Study participants
Patients aged 40–85 years with symptomatic radiographic 
primary femorotibial knee OA, Kellgren- Lawrence Grade (KLG) 
2 or 3, medial mJSW ≥2.5 mm in the target knee and a history 
of OA- related pain for 6 months (needing pain medication 
most days or scoring 4–9 on question A1 of the WOMAC pain 
index after pain medication washout at screening) were eligible. 
Exclusion criteria included secondary knee OA, malalignment 
>5° (based on the anatomic axis angle on weight- bearing radio-
graphs),18 clinical signs of inflammation in the target knee, 
planned surgery within 2 years and corticosteroids or hyaluronic 
acid administration to either knee 6 months before screening. All 
patients gave written informed consent.
RESULTS
Patient disposition
Of the 549 patients randomised (intention to treat (ITT)), 494 
(90%) were included in the modified ITT (mITT) analysis, 474 
(86%) completed treatment and the primary 2- year observation 
period and 442 (81%) and 378 (69%) completed the 3- year and 
5- year extended follow- up periods, respectively. At baseline, 
161 patients (29%) met the criteria for the SAR (figure 1). The 
most common reasons for discontinuation were ‘withdrawal of 
consent’ (n=63), followed by ‘other’ (n=52) and ‘adverse event’ 
(n=24).
The patients were 40–84 years old, with 69% being female 
(online supplemental table S1). Baseline characteristics, including 
age, sex, body mass index (BMI), mJSW and WOMAC pain were 
well balanced between study arms. The age, sex, race and BMI of 
patients in the ITT population and SAR were similar. The SAR, 
by definition of inclusion, had more severe disease than the ITT 
population, with a higher proportion of KLG 3 radiographic 
status (53% vs 31%).
Structural endpoints
The dose- dependent increase in TFTJ cartilage thickness by 
qMRI with sprifermin relative to placebo detected at year 2 was 
preserved to year 5 (trend test, p<0.001; figure 2A). In addition, 
the significant 0.05 mm adjusted mean increase in TFTJ cartilage 
thickness change between sprifermin 100 µg q6mo and placebo 
at year 2 was sustained to year 5 (0.049 mm; 95% CI 0.00 to 
0.10; p=0.015; figure 2B). Differences to placebo observed for 
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sprifermin 30 µg q6mo, 100 µg q12mo or 30 µg q12mo at year 
5 were not statistically significant. Results for the SAR at year 
5 were consistent with the mITT population, with an adjusted 
mean difference between the highest sprifermin dose and placebo 
of 0.06 mm (95% CI −0.02 to 0.14; p=0.129; figure 2C).
The adjusted mean difference in cartilage thickness change 
in the MFTC for the highest sprifermin dose compared with 
placebo was also maintained at approximately 0.05 mm at 
each timepoint from years 2–5, although not statistically 
significant after year 3 (95% CI −0.01 to 0.12; p=0.078 at 
year 5; figure 3A). The dose- effect of sprifermin on carti-
lage thickness change in the LFTC was preserved from years 
2 to 5 (trend test, p<0.05). The two highest sprifermin dose 
groups maintained an adjusted mean increase of 0.04 mm 
in LFTC compared with placebo to year 5 (100 µg q12mo: 
95% CI 0.00 to 0.09; p=0.03; 100 µg q6mo: 95% CI 0.00 to 
0.09; p=0.028; figure 3B). Results for the SAR at year 5 were 
consistent with the mITT population, with a mean difference 
between the sprifermin 100 µg q6mo and placebo groups of 
0.04 mm (95% CI −0.05 to 0.12) and 0.06 mm (95% CI −0.03 
to 0.14) in cartilage thickness change in MFTC and LFTC, 
respectively (figure 3C and D).
No effect of sprifermin on change from baseline in medial 
mJSW was observed at year 2 or up to year 5 (online supple-
mental figure S2A, table S2). Yet, a dose response was observed 
for lateral mJSW at each timepoint (p<0.05 at years 2–5). An 
adjusted mean difference in lateral mJSW change with spri-
fermin versus placebo of approximately 0.2 mm for the 100 µg 
groups was consistently observed over time, but not statis-
tically significant at year 5 (100 µg q12mo: 95% CI −0.09 
to 0.52; p=0.176; 100 µg q6mo: 95% CI −0.09 to 0.54; 
p=0.167; online supplemental figure S2B, table S2). For the 
SAR, a mean difference of 0.16 mm (95% CI −0.31 to 0.62) 
and −0.03 mm (95% CI −0.48 to 0.42) between the highest 
sprifermin dose and placebo for medial and lateral mJSW, 
respectively, was observed at year 5 (online supplemental 
figure S2C,D).
Symptomatic endpoints
The approximately 20- point (50%) improvement from baseline 
in WOMAC pain subscore at year 2 was maintained to year 5 
in all cohorts, including placebo (dose response: p=0.673; 
figure 4A, online supplemental table S3). There was no differ-
entiation in WOMAC pain between any sprifermin dose and 
placebo at year 5 in the ITT cohort; the adjusted mean differ-
ence for sprifermin 100 µg q6mo versus placebo was −1.06 (CI 
−9.10 to 6.99; p=0.990). These results were consistent with 
WOMAC total scores and WOMAC function subscale scores, 
which also improved by approximately 20 points (50%) from 
baseline to year 5 in all groups (online supplemental figure S3A, 
table S3). The adjusted mean difference in WOMAC total for 
sprifermin 100 µg q6mo versus placebo was −1.29 (CI −9.01 
to 6.43).
However, post hoc analysis of the SAR identified a significant 
dose- dependent improvement in WOMAC pain at year 3 that 
persisted to year 5 (dose response: p=0.046; figure 4B). Further, 
a clinically meaningful numerical difference in WOMAC pain 
scores between sprifermin 100 µg q6mo and placebo at year 3 
(adjusted mean −8.58; 95% CI −22.22 to 5.06) was sustained 
to year 5 (adjusted mean −10.08; 95% CI −25.68 to 5.53). In 
addition, the estimated mean difference in total WOMAC for 
the SAR between sprifermin 100 µg q6mo and placebo was clini-
cally significant and persisted to year 5 (−9.50; 95% CI −23.52 
to 4.53; online supplemental figure S3B).
Safety
The number of patients who reported AEs over 5 years was 
similar between the sprifermin groups (96%–98%) and placebo 
(98%; table 1). AEs were mostly mild or moderate in severity 
and 79% were deemed unrelated to treatment. Local AEs in the 
target knee were reported by 49%–51% sprifermin patients and 
49% with placebo (table 1). The greatest number of local related 
AEs were classified as musculoskeletal and soft tissue disorders, 
the most common being arthralgia; reported by 9%–13% of 
Figure 1 Patient disposition. One patient was randomised to placebo but received sprifermin 30 µg at visit 7 and one patient was randomised to 
sprifermin 30 µg q12mo but received 100 µg at visit 3; these patients were included in the 30 µg q12mo and 100 µg q12mo groups, respectively, for 
the SAF analysis set. ITT, intention to treat; mITT, modified intention to treat; N, total number; n, subgroup sample size; q6mo, every 6 months; q12mo, 
every 12 months; SAF, safety; SAR, subgroup at risk.
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patients receiving sprifermin and 9% receiving placebo. No new 
systemic or local safety concerns were identified.
A total of 181 patients (33%) reported serious AEs (SAEs). 
The incidence of SAEs was similar between the sprifermin 
(29%–38%) and placebo (36%) groups, and none were consid-
ered treatment related by investigators. The most common SAEs 
were OA and arthralgia. Withdrawals due to AEs were <10% in 
all treatment groups. The majority of these were musculoskeletal 
and soft tissue disorders. One patient in the placebo group died 
due to gastric cancer approximately 5 months after the last dose; 
this was not considered treatment related.
Safety results for the SAR were similar to the ITT population 
(table 1); there was no obvious difference between the sprifermin 
and placebo groups and approximately 80% of AEs were unre-
lated to treatment. There were more SAEs in the placebo (53%) 
than in the sprifermin groups (31%–37%) for patients in the SAR.
By the end of year 5, a total of 15 patients had partial or total KR 
of the treated joint (table 1). In the ITT population, the incidence 
of partial or total KRs in the treated joint was less than 5% in all 
groups including placebo (n=4, 4.6%), with the exception of the 
sprifermin 30 µg q6mo group (n=5, 5.4%). No patient in the spri-
fermin 100 µg q6mo group had replacement of the treated knee.
DISCUSSION
DMOADs that not only alleviate symptoms but also modify 
structure are an important and unmet clinical need for knee 
Figure 2 Change in TFTJ cartilage thickness up to year 5. (A) Absolute change from baseline in TFTJ cartilage thickness (mm) and (B) difference from 
placebo in TFTJ cartilage thickness (mm) for the mITT population (n=494). (C) Absolute change from baseline in TFTJ cartilage thickness (mm) and 
(D) difference from placebo in TFTJ cartilage thickness (mm) for the SAR (n=161). Means and 95% CIs shown. *p<0.05, **p<0.005, ***p<0.001. BL, 
baseline; mITT, modified intention to treat; q6mo, every 6 months; q12mo, every 12 months; SAR, subgroup at risk; TFTJ, total femorotibial joint.
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OA. Sufficient follow- up in DMOAD trials may be necessary to 
demonstrate that the structural benefit of a DMOAD is main-
tained and that structure modification eventually translates 
into clinical benefit. FORWARD is the longest DMOAD study 
reported to date. The results of the current analyses show that 
the efficacy of sprifermin, as measured by both the dose- effect 
and the mean difference versus placebo in TFTJ cartilage thick-
ness at year 2, was maintained up to year 5, that is, for at least 
3.5 years post- active treatment. These findings suggest that 
intra- articular sprifermin has a sustained effect on articular carti-
lage modification in patients with knee OA, with no detectable 
systemic exposure or new safety signals observed up to Year 5.
Evaluation of the type of cartilage gained with sprifermin by 
biopsy was not possible in FORWARD due to ethical consider-
ations. Preclinical studies in rat models of OA indicated that spri-
fermin induces the proliferation of hyaline cartilage- producing 
articular chondrocytes, hyaline extracellular matrix synthesis 
and cartilage repair.8 10 11 Importantly, the cartilage gained with 
sprifermin treatment up to year 2 did not decline at a faster 
rate after the end of treatment than the natural cartilage in the 
placebo group, indicating robust quality and mechanical proper-
ties with similar resilience to natural cartilage.
Statistically significant cartilage modification was observed in 
the LFTC with sprifermin and while the 0.05 mm net increase in 
Figure 3 Change in MFTC and LFTC cartilage thickness up to year 5. Difference from placebo in cartilage thickness (mm) in the (A) MFTC and 
(B) LFTC for the mITT population (n=494). Absolute change from baseline in (C) MFTC and (D) LFTC cartilage thickness (mm) for the SAR (n=161). 
Means and 95% CIs shown. *p<0.05, **p<0.005, ***p<0.001. BL, baseline; LFTC, lateral femorotibial compartment; MFTC, medial femorotibial 
compartment; mITT, modified intention to treat; q6mo, every 6 months; q12mo, every 12 months; SAR, subgroup at risk; TFTJ, total femorotibial joint.
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MFTC thickness with sprifermin versus placebo was maintained 
to year 5, it was not statistically significant. Since the majority 
of patients in the study had medial disease, less weight load in 
the lateral compartment (off- loading the joint) may have allowed 
for a more pronounced effect by sprifermin in the LFTC. Impor-
tantly, the medial compartment responded to sprifermin despite 
continuous weight load.
A large decrease in WOMAC pain of approximately 50% was 
observed in all groups, including placebo, and maintained up 
to year 5. These observations suggest that the contextual effect 
of intra- articular injection that is known to impact WOMAC 
outcome in knee OA trials19 is maintained over long periods. 
This is in line with a meta- analysis of 32 randomised trials that 
showed intra- articular saline injections to significantly improve 
short- term and long- term knee pain.20 There was high variation 
in WOMAC pain and no statistical differentiation between 
the highest sprifermin dose and placebo was observed in the 
ITT cohort at year 5 or previous timepoints. FORWARD was 
designed to assess structural modification, not symptoms, and as 
such pain medication was not modified or restricted throughout 
the study. This may have contributed to the lack of symptomatic 
differentiation between sprifermin and placebo.
Post hoc analyses identified a subgroup of patients with 
narrower mJSW (<3.5 mm) and non- acceptable OA- related 
knee pain (>40) at baseline: the SAR.16 Interestingly, net struc-
tural improvement in cartilage thickness relative to placebo was 
similar in the SAR and overall study population, although the 
SAR encountered more rapid cartilage loss compared with the 
latter. This is an important finding, as it is often presumed that 
DMOADs would be ineffective in patients with more severe 
Figure 4 Change from baseline in WOMAC pain scores up to year 5 in the (A) ITT population (n=549) and (B) SAR (n=161). Means and 95% CIs 
shown. Δajd., adjusted mean difference (95% CI) to placebo at year 5; BL, baseline; ITT, intention to treat; q6mo, every 6 months; q12mo, every 12 
months; SAR, subgroup at risk; WOMAC, Western Ontaria and McMaster Universities Osetoarthritis Index.
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disease at baseline and in those with faster structural progres-
sion. The current results, however, demonstrate that structural 
modification by sprifermin is at least as strong in more severe 
OA as in milder OA.
The overall study population was relatively heterogeneous 
due to the inclusion criteria allowing a population with 
diverse levels of baseline pain and structural status. A shift 
in pain reporting between screening (WOMAC sub- question 
A1) and baseline (sub- questions A1–A5) was observed, and a 
relatively high proportion of patients (32%) had a baseline 
WOMAC pain score of <40. Such heterogeneous cohorts 
may be less likely to differentiate DMOAD responses on 
pain from placebo due to a floor effect that contributes to 
lower average scores across the study population.16 Patients 
were selected with different amounts of cartilage thickness 
at baseline in order to maximise the likelihood of observing 
structural changes. As a result, many patients (38%) had a 
baseline medial mJSW of >4.0 mm that approached the JSW 
of healthy individuals. It is likely that more time is required 
for these patients to show translation of structural improve-
ment to symptomatic benefit versus placebo.
Importantly, and in contrast with the full ITT cohort, the 
potential clinically meaningful improvements in pain with 
the highest sprifermin dose versus placebo observed at year 
3 were sustained to year 5 in the SAR. The pain benefit of 
sprifermin in this subgroup required 2–3 years to become 
clinically relevant, in line with the hypothesis that this occurs 
subsequent to structural modification of cartilage thickness. 
These results are plausible, as patients with less mJSW, lower 
cartilage thickness and more pain at baseline are more likely 
to symptomatically benefit from cartilage structural modi-
fication than those with only mild disease. The findings 
also show that relatively long observation intervals may be 
required to demonstrate the translation of structural modifi-
cation into symptomatic benefit.
The limitations of this study include that the year 5 anal-
yses were exploratory, and the SAR was identified post hoc 
and included a modest proportion of patients. Conclusions 
regarding sprifermin’s symptomatic effects are limited by the 
lack of control/modification of analgesic medication during 
the study (as per protocol) and the enrolment of patients with 
limited pain at baseline. No techniques were applied to iden-
tify valid pain reporters or limit the placebo effect on pain. 
Rescue medications and changes in physical activity were not 
analysed, which could have helped put into context the lack 
of separation in symptomatic endpoints between the spri-
fermin and placebo groups. Finally, MRI reading approaches 
regarding blinding to the sequence of image acquisition 
differed between time points, although differences between 
sprifermin- treated and placebo- treated patients at each time 
point were unaffected by this.
In conclusion, these findings suggest potential long- lasting 
cartilage structural modification with sprifermin treatment 
among patients with knee OA. Symptomatic improvements 
with sprifermin versus placebo were observed in an SAR of 
structural and symptomatic progression. The FORWARD 
trial had the longest follow- up time for DMOAD efficacy 
using quantitative imaging and provides an exemplar for 
the feasibility of long- term OA trials. Enrichment of patient 
populations with higher likelihood of structural and symp-
tomatic progression may increase the chance of successful 
DMOAD development.
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for publication. FE, MH, HG, FM, ARB and JRA were involved in the study design and 
Table 1 Summary of AEs and KRs in the ITT population (n=547) and SAR at year 5 (n=161)
Patients, n (%)
ITT SAR
























All AEs 105 (98.1) 107 (98.2) 109 (98.2) 107 (96.4) 107 (98.2) 34 (100.0) 35 (97.2) 27 (100.0) 31 (100.0) 33 (100.0)
  Local AEs 52 (48.6) 54 (49.5) 57 (51.4) 54 (48.6) 53 (48.6) 18 (52.9) 17 (47.2) 13 (48.1) 18 (58.1) 12 (36.4)
  Systemic AEs 103 (96.3) 104 (95.4) 105 (94.6) 105 (94.6) 106 (97.2) 34 (100.0) 35 (97.2) 27 (100.0) 31 (100.0) 33 (100.0)
All SAEs 39 (36.4) 35 (32.1) 34 (30.6) 32 (28.8) 41 (37.6) 18 (52.9) 11 (30.6) 10 (37.0) 11 (35.5) 12 (36.4)
  Local SAEs 5 (4.7) 4 (3.7) 6 (5.4) 3 (2.7) 1 (0.9) 4 (11.8) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0)
  SAEs leading to death 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
KRs* 4 (4.6) 4 (4.0) 5 (5.4) 2 (2.0) 0 (0.0) 3 (8.8) 1 (2.8) 1 (3.7) 0 (0.0) 0 (0.0)
*The incidence of partial or total replacement of the treated knee at year 5, presented as a percentage of patients who completed year 2 per group (placebo, N=87; 30 µg 
q12mo, N=99; 30 µg q6mo, N=92; 100 µg q12mo, N=98; 100 µg q6mo, N=96).
AEs, adverse events; ITT, intention to treat; KRs, knee replacements; q6mo, every 6 months; q12mo, every 12 months; SAEs, serious adverse events; SAR, subgroup at risk.
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